Initial results of megavoltage computed tomography (MVCT) brachytherapy treatment planning are presented, using a commercially available helical tomotherapy treatment unit and standard low dose rate (LDR) brachytherapy applicators used for treatment of cervical carcinoma. The accuracy of MVCT imaging techniques, and dosimetric accuracy of the CT based plans were tested with in-house and commercially-available phantoms. Three dimensional (3D) dose distributions were computed and compared to the two dimensional (2D) dosimetry results. Minimal doses received by the 2 cm 3 of bladder and rectum receiving the highest doses (D B2cc and D R2cc , respectively) were computed from dose-volume histograms and compared to the doses computed for the standard ICRU bladder and rectal reference dose points. Phantom test objects in MVCT image sets were localized with sub-millimetric accuracy, and the accuracy of the MVCT-based dose calculation was verified. Fifteen brachytherapy insertions were also analyzed. The ICRU rectal point dose did not differ significantly from D R2cc (p=0.749, mean difference was 24 cGy ± 283 cGy). The ICRU bladder point dose was significantly lower than the D B2cc (p=0.024, mean difference was 291 cGy ± 444 cGy). The median volumes of bladder and rectum receiving at least the corresponding ICRU reference point dose were 6.1 cm 3 and 2.0 cm 3 , respectively. Our initial experience in using MVCT imaging for clinical LDR gynecological brachytherapy indicates that the MVCT images are of sufficient quality for use in 3D, MVCT-based dose planning.
Introduction
The availability of more powerful radiation therapy treatment planning computers and greater availability of computed tomography (CT) imaging has led to the widespread replacement of 2D external beam planning techniques by 3D dose planning. This also applies to certain aspects of brachytherapy, notably permanent prostate seed implants and some high dose rate brachytherapy implants. Unlike most teletherapy planning situations, the practitioner finds in attempting CT-based brachytherapy planning that many brachytherapy applicators are not CT compatible, due to the large degree of attenuation of the kV x-ray CT beam by the metal components of many applicators. Without CT compatible applicators, most practitioners utilize some variety of 2D dosimetry planning techniques, usually based on plane radiographs. Our institution has recently begun investigation of a megavoltage CT (MVCT) imaging technique with a commercially available helical tomotherapy treatment unit (Tomotherapy HiArt, Tomotherapy Inc., Madison WI) (1-5). The HiArt unit utilizes a nominal 6 MV linear ac-Technology in Cancer Research & Treatment, Volume 8, Number 2, April 2009 celerator mounted in an enclosed rotating gantry to perform MVCT imaging of the patient for treatment alignment, and to deliver intensity-modulated radiation therapy treatments. The high energy of the MVCT imaging beam (about 3.5 MV) permits CT imaging of non-CT compatible (metallic) objects with less reconstruction artifact. This greatly facilitates the use of CT-based, three dimensional dosimetry techniques for gynecological brachytherapy implants. Figures  1a and 1b show a 120 kVp CT image of a standard Fletcher-Suit applicator, and an MVCT image of the same applicator acquired with the helical tomotherapy unit at about 3.5 MV (1) in a plane passing through the shielded colpostats, respectively. The improved visualization of the brachytherapy applicator in the MVCT image suggests a possible use for MVCT images in brachytherapy planning.
The work presented here follows other studies of three dimensional brachytherapy planning of intracavitary implants that have traditionally been planned using only two-dimensional methods. This report focuses on a novel application of a helical tomotherapy unit to acquire MVCT images for the 3D brachytherapy planning. For a more detailed discussion of transitioning from 2D to 3D intracavitary planning, the reader is referred to other sources (6, 7) .
Materials and Methods: MVCT Images
MVCT images present some challenges in treatment planning that kV-range radiographic or tomographic images do not. Materials that ordinarily provide significant contrast in the kV photon range do not provide nearly as much contrast in the MV photon range. Thus, in imaging to plan a clinical implant (applicator in vivo), MVCT images present a difficulty in using the images due to the megavoltage energy of the x-rays. Specifically, the Foley balloon catheter, which is normally placed in the patient's bladder and subsequently filled with non-ionic iodinated contrast agent, offers much less contrast on MVCT images than on conventional kV CT or radiographic images. The Foley balloon is even less visible when viewed on DRRs derived from MVCT images. Likewise, even when contrast-enhanced gauze is used in packing placed between the ovoids and the posterior vaginal wall, it is very difficult to discern on MVCT images or on DRRs derived from MVCT images. Our approach to this difficulty was to contour the Foley catheter balloon on axial MVCT images, using the virtual simulation tools included in our treatment planning system, and to then view the reconstructed contours of the balloon on the DRRs. The posterior wall of the vagina (as determined by the visibility of radio-opaque gauze packing) was much more difficult to discern, even in the cases where such packing was used. Generally, this packing can not be visualized on MVCT images or on MVCT DRRs.
The spatial accuracy of localizing objects in MVCT image sets was tested with a commercially available stereotactic localization phantom (8). This phantom has six aluminum spheres with known stereotactic coordinates. The phantom was imaged on our tomotherapy unit, the test object spheres localized in commercially available software (BrainScan 5.0, BrainLAB AG, Munich, Germany), and the locations compared with the mechanically measured locations provided by the phantom manufacturer (Varian Medical Systems, Palo Alto, CA). The sphere locations were determined by placing a spherical cursor over the image of each sphere in axial, sagittal, and coronal reconstructed planes. Images were acquired with "fine" helical pitch, which on our unit yields image sets with 2.0 to 2.5 mm slice thickness and 0.75 mm pixel size on 512 × 512 axial MVCT images.
Materials and Methods: 2D and 3D Dose Calculation
Our institution's treatment planning system (Computerized Medical Systems XiO 4.2, St. Louis MO) allows brachytherapy source and interest point localization to be performed with either a 2D, radiographic film and digitizer based method, or by identifying points in a 3D CT image set. Dose calculations with this planning system were performed using the AAPM TG-43 methodology (9, 10) with a line source geometry function, and assuming an infinite water medium without heterogeneity corrections. Dose calculation accuracy by the treatment planning system with the commissioned Cs-137 sources was verified by comparison of a number of point doses around a single Cs tube source with dose rate values in the literature (11). The treatment planning system dose calculation for multiple sources in known, simple geometries was also tested prior to use. Since using the system in a 3D, image set mode is a departure from our normal 2D, radiograph-based clinical dosimetry, consistency of dose calculation between the two modes was verified. Dose computation consistency between 2D and 3D brachytherapy dose computations was tested with a locallyprepared test phantom ( Figure 2 ). The phantom consists of a standard Fletcher-Suit applicator (Best Medical Inc., Springfield, VA) fixed to a styrofoam bed, in which six steel spheres of 4 mm diameter were embedded, approximating the locations of standard dosimetric points. Dummy markers consisting of a train of steel spheres at 1 cm intervals were loaded into the tandem, and 2cm steel pin dummy sources were loaded in the ovoid portions of the applicator. The train of dummy spheres provides a reference point (the CT center of each sphere) at 1 cm intervals rather than 2 cm intervals as is the case for 2 cm long dummy sources, plus some length of spacer material placed between dummy sources to distinguish one dummy source from another. MVCT images of the phantom were acquired with the same parameters used for the spatial accuracy testing. After importing the MVCT images into the planning system, the steel sphere dose point markers were contoured, and anterior-posterior and lateral DRRs were generated ( Figure 3 ). The DRRs were printed on paper, and the planning system's digitizer tablet used to perform standard 2D dosimetry at the test points for a simulated source loading with dummy Cs-137 tube sources (3M Model 6500, 2 cm physical length and 1.4 cm active length). Using the planning system in CT-based, 3D mode, points were placed at the center of each contoured steel sphere marker, and the same source loading duplicated as the 2D simulated plan by localizing source tip and ends in MVCT axial images. The doses (dose rates) to the steel sphere test points localized via 2D and 3D methods were compared. Dose calculations in patient cases were performed by identifying source tips and end coordinates in MVCT images, using the treatment planning system's mouse and graphics display. The locations of standard dosimetry point locations (Manchester A and B points, ICRU rectal and bladder dose points) were determined by the use of small, circular-shaped (< 1 mm diameter) dummy structures occupying a single MVCT slice. Each dummy structure was moved through the MVCT image set as needed so that it's projected location in AP and lateral DRRs matched the appropriate location for the corresponding point in a conventional radiograph-based, two-dimensional dosimetry system, after which points of interest could be precisely placed in the center of each dummy structure. Exact placement of the Manchester system A and B points was facilitated by using the corners of virtual beams, respectively, whose isocenters were placed at approximately the external os. For instance, when viewing the DRR from a 4 cm × 4 cm virtual AP beam centered on the external os, the superior outer corners of the beam will lie 2 cm superiorly Figure 2 : Dosimetry test phantom consisting of standard Fletcher-Suit applicator, dummy steel sources loaded into ovoids, and locally-prepared tandem dummy sources. A set of six spheres were embedded in the styrofoam to serve as test object points/structures, which would be visible in 2D radiographic images, as well as in 3D MVCT images. and ± 2 cm laterally from the beam's isocenter, corresponding to the location of the Manchester A points. A similar AP 4 cm × 10 cm beam, with collimator rotated as necessary to match the patient's centerline, can be used to place Manchester B points 2 cm superiorly and ± 5 cm laterally. Figure 3 demonstrates this for placement of the B points. An isotropic dose grid resolution of 1mm was used. Dose-volume histograms for the bladder and rectum were computed for each implant.
Methods: Brachytherapy Implants and MVCT-based Dose Calculations
Between January 2005 to April 2006, ten patients at our institution received standard Fletcher-Suit GYN LDR brachytherapy (twenty implants). MVCT image sets were acquired and analyzed during fifteen of these implants. Patients undergoing MVCT imaging were implanted with standard Fletcher-Suit applicators (Best Medical International, Springfield VA). Standard plane radiographic images of the patient and implant were acquired, followed by an MVCT imaging session on our tomotherapy unit. Implants were planned and treated with standard anterior-posterior and lateral radiographic image techniques. Three-dimensional dose calculations based on the MVCT image sets were performed afterwards. "Fine" MVCT helical pitch was used, which produces an MVCT image set with 2.0 to 2.5 mm slice thickness and a 0.75 mm pixel size for 512 × 512 axial CT images. The MVCT images were transferred to the treatment planning system, where the bladder, bladder catheter balloon, and rectum were contoured. For purposes of visualization, the brachytherapy applicator was also contoured. Standard dose points (A and B points, bladder and rectal reference points) were located within the MVCT image set by use of DRRs. Each patient's two brachytherapy implants were planned following 45 Gy of external beam radiotherapy to deliver a total average point A dose of 80 Gy, without exceeding about 65 Gy total dose to the ICRU rectal dose point and 70 Gy to the bladder point. An MVCT orthogonal isodose display for a typical implant is shown in Figure 4 . Dose volume histograms (DVHs) were computed and used to determine the minimal doses received by the most exposed 2 cm 3 of bladder and rectum [D B2cc and D R2cc , respectively, using the notation of Potter et al. (7)], as well as the volumes of bladder and rectum receiving at least the dose received at the standard ICRU reference points. Paired sample statistics (two-sided t-test) were used to compare the doses to ICRU bladder and rectal points with D B2cc and D R2cc , respectively. A two-sided t-test was used to compare ratios of the doses to ICRU bladder point and D B2cc , and of the ICRU rectal point dose and D R2cc , to unity.
Results
The absence of reconstruction artifact in MVCT images near high-Z materials is distinctly better than in kVCT images (Figures 1a, 1b) . Table I lists the CT numbers for regions of interest for a Fletcher-Suit applicator in air immediately outside of the applicator colpostats, and several centimeters away from the colpostat. In the kVCT image, the reconstruction streak artifact near the colpostats causes the kVCT number in air, -722, to be higher than expected (-1000). The corresponding region in the MVCT image has an average MVCT number of -935. Several cm further away from the colpostats and the worst of the reconstruction artifact, the CT numbers in a region of air in the kVCT and MVCT image sets have gone down to a more normal average -1009 and -990, respectively. Figure 1a illustrates the in vivo appearance of a standard Fletcher-Suit-Delclos applicator (Best Medical International, Springfield VA) in an MVCT image (acquired during the first of two implants), while Figure 1b shows a kVCT image of the same patient. The mean and standard deviation of CT numbers in regions of muscle and adipose tissue in each image were analyzed with publicly available image analysis software (12). The MVCT images offer poorer contrast resolution than do conventional kVCT images, but are nevertheless of sufficient quality to permit the distinction of Figure 1a , muscle tissue in this MVCT image (region of interest average MVCT number -53) can be distinguished from the background of adipose tissue (region of interest average MVCT number -104). The difference in electron density of muscle in an adipose tissue background is about 9.4%, using reference electron density values (13). From previously conducted characterization of MVCT image contrast resolution and detail at our institution (14), a typical observer could discern an object at 9.4% electron density contrast from background, which is about 5 mm in diameter. The muscle tissue in Figure 1a in which the region of interest was taken is about 2.5 cm across its narrowest dimension. The comparison kVCT image of the same patient (Figure 1b ) shows a larger difference in average (kV) CT numbers in muscle relative to fat (40 for muscle relative to -129 for fat, a difference of 169 Houndsfield units). Thus, while the MVCT images are not as well-suited for the distinction of soft tissues as are kVCT images, they still offer sufficient contrast for this purpose.
The mean and standard deviation of the vector error in localizing the stereotactic test objects in MVCT image sets was 0.63 mm ± 0.25 mm, respectively. This is comparable to the vector error measured when performing the same phantom objects with conventional kVCT image sets (0.79 mm ± 0.08 mm) acquired with our department's CT simulator (PQ-2000S, Philips Medical Systems, Andover, MA). MVCT anterior-posterior and lateral direction errors each averaged 0.2 mm, and cranio-caudal direction errors averaged 0.5 mm, less than half a slice thickness.
Dose rates for the 2D and 3D plans were computed at each of six BB marker points and compared. Dose rates for the same point agreed to within 2.5% ± 1.8% (average ± standard deviation). This confirmed the consistency of point doses calculated using the planning system in 2D and 3D modes, and also confirmed our ability to consistently identify and calculate dose to 2D standard dose points within a 3D image set.
The ratio of D R2cc to ICRU rectal point dose did not differ from unity (p=0.360); the ratio of D B2cc to ICRU bladder point dose differed from unity (p=0.008). The ICRU rectal point dose (Figures 5, 7) did not differ significantly from D R2cc (Table II, p=0.749, mean difference ± standard deviation was 24 cGy ± 283 cGy). The ICRU bladder point dose (Figures 6, 7) was significantly lower than the D B2cc (Table II, p=0 .024, mean difference 291 cGy ± 444 cGy). The mean volume of bladder receiving at least the ICRU bladder dose was 9.6 ± 13.3 cm 3 , and the mean volume of rectum receiving at least the ICRU rectal point dose was 4.6 ± 4.9 cm 3 . The median volume of bladder receiving at least the ICRU bladder dose was 6.1 cm 3 , and the median volume of rectum receiving at least the ICRU rectal point dose was 2.0 cm 3 . The maximum 3D bladder dose was higher than the ICRU bladder point dose by a factor of as much as 2.3, and the maximum 3D rectal dose was higher than the ICRU rectal point dose by a factor of as much as 1.59. The 3D maximum bladder and rectal point doses differed significantly from the corresponding ICRU reference point doses (Table III, p<0 .001 for both bladder and rectum). Our data seem in agreement with a recent volumetric dose study of LDR GYN implants by Pelloski et al. (15, 16) , and suggest that the ICRU rectal point dose may be an acceptable surrogate for D R2cc , but that the ICRU bladder point dose is not an acceptable surrogate for D B2cc . Neither the rectal nor the bladder ICRU reference point doses are an acceptable surrogate for each structure's 3D maximum dose.
Discussion
The relationship between 3D and traditional 2D point dose dosimetry is complex and is an area of active investigation. Similar to the transition from 2D to 3D dosimetry in external beam radiotherapy, there may not yet be enough evidence to definitively link, which 3D dose-volume parameters are most clinically relevant, and directly relatable to the extensive 2D planning expertise that has been accumulated over a number of decades. In low dose rate brachytherapy for cervical carcinoma, transitioning from 2D to 3D dosimetry is complicated (relative to the 2D to 3D external beam experience a decade ago) by the need not just for greater computing capability (which has been widely available since the advent of 3D planning for external beam radiotherapy), but for high quality 3D imaging. For low dose rate brachytherapy for cervical carcinoma, this generally has been accomplished through the use of special, CT-compatible applicators (17), which to date have generally suffered the disadvantages of higher cost, larger size, and reduced structural strength and durability due to the special materials of which they are constructed (18, 19) . These applicators frequently also eliminate the rectal and bladder shielding in the colpostats, which while reducing or eliminating CT image artifact, also increases the bladder and rectal doses delivered. Some investigators have used standard, non-CT compatible applicators with standard kVCT imaging, accepting a reduction in image quality and extensive reconstruction artifact in the vicinity of the applica-tor (especially the shielded colpostats) (15, 16, 20) . Until the recent availability of MVCT imaging, one or more of these compromises were necessary in order to perform 3D low dose rate brachytherapy for cervical carcinoma. As shown by the clinical example case above, MVCT imaging permits the use of standard, unmodified brachytherapy applicators for 3D brachytherapy dosimetry planning, without any of the compromises which have until now been necessary. MVCT imaging for gynecological brachytherapy yields sufficient image quality for soft-tissue delineation, with good image quality and little CT reconstruction artifact throughout the image set, including directly in the vicinity of shielded, standard Fletcher-Suit-Delclos applicator colpostats. The ability to routinely perform 3D, CT based brachytherapy dosimetry also offers the potential to determine doses to other structures otherwise not available, such as the pelvic lymph nodes (21). At present there are no commercially available brachytherapy treatment planning systems that incorporate heterogeneity corrections in the manner commonly available now in external beam treatment planning. However, lesser amount of reconstruction artifact in MVCT images should result in more accurate heterogeneously corrected dose calculations, when these systems become available in the future. This is potentially significant, since the ovoid shielding in a standard Fletcher-Suit applicator may reduce the radiation dose opposite the shield by as much as 50% (22). The increasing popularity and numbers of helical tomotherapy units in clinical use will also hopefully increase the opportunity for more clinicians to routinely perform 3D brachytherapy planning for gynecological low dose rate brachytherapy. The primary motivation for acquiring a helical tomotherapy unit is of course to use it for image-guided, intensity-modulated radiotherapy. But, the MVCT imaging capabilities of a tomotherapy unit can offer unexpected additional benefits such as the ability to perform 3D intracavitary brachytherapy planning without the use of special CT and MR compatible brachytherapy applicators.
